NovoCure Limited Stock News

The central bank's plan to aggressively hike interest rates might trigger a sharp correction in U.S. stock markets. Axon Enterprise and NovoCure are two companies with economically insensitive busines

Investors were looking for a stronger Q4 from the cancer company.

Novocure Limited (NASDAQ:NVCR ) Q4 2022 Results Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Execut

NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

There was good news from the laboratory on Hump Day.

As NovoCure Limited delivers hope in seemingly hopeless situations, Tumor Treating Field is already launched for mesothelioma and glioblastoma multiforme. NovoCure Limited recently generated stellar d

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.

Novocure announced a series of exec changes on Thursday as investor debate continues to haunt its recent study. NVCR stock tumbled again.

The stock has both soared and sank already this year.

Novocure will win a 10% of its targeted lung cancer market, an analyst predicted Tuesday as he examined NVCR stock's double-digit drop. The post Novocure Has Fallen More Than 20% Over Seven Days — W

Powered by the robust Phase 3 (LUNAR) trial, NovoCure Limited shares recently rallied over 70% in one trading session. You can expect Tumor Treating Field to be approved for non-small cell lung cancer

The company provided a disappointing sneak peek at its Q4 results.

Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?

Here's why Novocure stock popped over 68% on Jan. 5.